David Silverman is an associate member of Cadwalader's Firm Committee whose practice is concentrated in the area of corporate law, with an emphasis on private equity, mergers and acquisitions, hedge funds, venture capital and corporate finance. David represents clients in complex transactions, including leveraged buyouts, mergers and acquisitions, distressed transactions, hedge fund formation and private security offerings. His clients include private equity funds and their portfolio companies, venture capital investors, large corporate entities, global investment banks and investment managers.
David received his J.D., cum laude, from Boston University, where he was a member of the Review of Banking & Financial Law, the country's leading scholarly banking and financial law journal. He received his B.A. summa cum laude and Phi Beta Kappa from Binghamton University. David Silverman is admitted to practice in the State of New York.
Representative transactions on which David has worked include:
•The Goodyear Tire & Rubber Company in connection with the dissolution of its global alliance with Sumitomo Rubber Industries, Ltd.
•CVC Capital as a founding investor in Fidelis Insurance Holdings Limited, a newly formed Bermuda-based specialty insurance company.
•A global investment bank in connection with multiple investments in real estate development joint ventures.
•DoubleLine Capital LP in connection with its formation and entry into a joint venture arrangement with Oaktree Capital Management, L.P.
•A private equity firm in the formation of a joint venture with a privately held maritime company.
•The management team of Medpace Holdings, Inc. in connection with its $930 million leveraged recapitalization sponsored by Cinven.
•A number of venture capital firms in preferred stock, convertible note and common stock financings of emerging software and technology companies.
•Toba Capital in multiple investments in domestic and multinational software companies.
•OrbiMed Advisors LLC in more than three dozen investments in domestic and multinational life sciences companies.
•The Chairman and Chief Executive Officer of Quest Software, Inc. in connection with its $2.4 billion sale to Dell, Inc.
•CVC Capital Partners in its $4.4 billion agreement to acquire the iShares ETF business from Barclays.
•An asset manager in connection with the formation of a number of hedge funds.